Cancer Discov. 2023 May 4;13(5):1033-1034. doi: 10.1158/2159-8290.CD-NB2023-0018.
The CodeBreaK 200 trial showed that sotorasib led to a 34% decrease in relative risk of disease progression or death compared with docetaxel but yielded no improvement in overall survival. Despite the KRAS inhibitor's high cost, less toxicity likely tips the balance in its favor. Subgroup analyses and combination trials are underway to optimize treatment with sotorasib and other KRAS inhibitors.
CodeBreaK 200 试验表明，与多西他赛相比，索托拉西布可使疾病进展或死亡的相对风险降低 34%，但对总生存期没有改善。尽管 KRAS 抑制剂价格昂贵，但毒性较低可能使其更具优势。正在进行亚组分析和联合试验，以优化索托拉西布和其他 KRAS 抑制剂的治疗。
